INCY Incyte Dashboard

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Company profile

Ticker

INCY

Exchange

NASDAQ

Website

www.incyte.com/

CEO

Herve Hoppenot

Incorporated

Delaware

Location

Delaware

Fiscal year end

Dec 31

Sector

Professional, Scientific, and Technical Services > Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)

Industry (SIC)

Services - Commercial Physical & Biological Research

PPD • IQVIA • PRA Health Sciences • Syneos Health • Icon • Medpace • Charles River Laboratories International • Exact Sciences • National Research • Inotiv ...

Former names

INCYTE GENOMICS INC, INCYTE INC, INCYTE PHARMACEUTICALS INC

SEC CIK

0000879169

Corporate docs

Articles of Incorporation & Bylaws

IRS number

943136539

INCY stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data

8 Apr 21

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7)

Eli Lilly-Incyte's Baricitinib Study In Hospitalized COVID-19 Patients Fails To Meet Main Goal

8 Apr 21

The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award

7 Apr 21

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 6)

Morgan Stanley Maintains Equal-Weight on Incyte, Lowers Price Target to $86

5 Apr 21

Incyte's Pemazyre Wins European Approval For Bile Duct Cancer

29 Mar 21

Press releases

Pro users get this 30m faster

Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients

8 Apr 21

INDIANAPOLIS, April 8, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care

Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis

6 Apr 21

INDIANAPOLIS, April 6, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the

Incyte Announces the European Commission Approval of Pemazyre® (pemigatinib) as a Treatment for Adults with Locally Advanced or Metastatic Cholangiocarcinoma with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement

29 Mar 21

- Pemazyre is the first targeted therapy approved in the EU for this indication Incyte (NASDAQ:INCY) today announced that the European Commission (EC) has approved Pemazyre® (pemigatinib) for the treatment of

Incyte Announces Approval of Pemazyre® (pemigatinib) in Japan for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene, Worsening After Cancer Chemotherapy

23 Mar 21

Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation

18 Mar 21

Calendar

9 Feb 21

11 Apr 21

31 Dec 21

Financial summary

Financial statements Chart INCY financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Incyte earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	1.51B	1.51B	1.51B	1.51B	1.51B	1.51B
Cash burn (monthly)	(positive/no burn)	26.58M	(positive/no burn)	21.97M	(positive/no burn)	10.38M
Cash used (since last report)	n/a	90.17M	n/a	74.55M	n/a	35.23M
Cash remaining	n/a	1.42B	n/a	1.44B	n/a	1.48B
Runway (months of cash)	n/a	53.6	n/a	65.5	n/a	142.5

Beta Read what these cash burn values mean

Recent insider trades

INCY insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Apr 21	Dhanak Dashyant	Common Stock	Sell	Dispose S	No	Yes	81.57	396	32.3K	27,336
31 Mar 21	Baker Bros. Advisors	Common Stock	Grant	Aquire A	Yes	No	0	364	0	29,314,516
31 Mar 21	Baker Bros. Advisors	Common Stock	Grant	Aquire A	Yes	No	0	364	0	2,850,749
31 Mar 21	Clancy Paul J	Common Stock	Grant	Aquire A	No	Yes	81.27	298	24.22K	5,094
31 Mar 21	Dixon Wendy L	Common Stock	Grant	Aquire A	No	Yes	81.27	225	18.29K	14,878
31 Mar 21	Harrigan Edmund	Common Stock	Grant	Aquire A	No	Yes	81.27	219	17.8K	2,711

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

INCY institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

92.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	486	484	+0.4%
Opened positions	67	64	+4.7%
Closed positions	65	60	+8.3%
Increased positions	177	173	+2.3%
Reduced positions	164	178	-7.9%

13F shares	Current	Prev Q	Change
Total value	19.83B	17.93B	+10.6%
Total shares	202.54M	199.86M	+1.3%
Total puts	731.8K	692.6K	+5.7%
Total calls	598.3K	798.8K	-25.1%
Total put/call ratio	1.2	0.9	+41.1%

Largest owners	Shares	Value	Change
TROW T. Rowe Price	32.59M	$2.84B	+5.4%
Baker Bros. Advisors	32M	$2.78B	+0.0%
Vanguard	20.16M	$1.75B	-1.6%
BLK Blackrock	17.81M	$1.55B	+4.4%
Wellington Management	13.5M	$1.17B	-4.4%
STT State Street	8.69M	$755.78M	-0.4%
Capital International Investors	6.79M	$590.58M	-8.1%
Renaissance Technologies	5.89M	$512.24M	-5.1%
Geode Capital Management	3.25M	$282.39M	+1.3%
Dodge & Cox	3.25M	$282.91M	-1.1%

Largest transactions	Shares	Bought/sold	Change
Norges Bank	1.88M	+1.88M	NEW
TROW T. Rowe Price	32.59M	+1.68M	+5.4%
IVZ Invesco	1.04M	-1.62M	-61.1%
ARK Investment Management	1.78M	+1.2M	+207.7%
GS Goldman Sachs	513.29K	-788.5K	-60.6%
BLK Blackrock	17.81M	+753.01K	+4.4%
Polar Capital	636.01K	+636.01K	NEW
Wellington Management	13.5M	-616.88K	-4.4%
Capital International Investors	6.79M	-600.31K	-8.1%
POLR Polar Capital	0	-585.93K	EXIT

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Geron • CTI BioPharma • Exelixis • Curis • Infinity Pharmaceuticals • Lumos Pharma • Sierra Oncology • AVEO Pharmaceuticals • AnaptysBio • SELLAS Life Sciences

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: adaptive, AEs, aggressive, aid, AIHA, Allergy, ancestry, appetite, arm, ascertain, ASCT, ASH, baccalaureate, BAT, benchmarking, bendamustine, binary, BIRC, Black, Blinded, BOR, BRAVE, broaden, Brown, budgetary, Canada, Canadian, canal, carefully, caution, CCA, CCPA, Cohort, color, compliant, compromise, confidence, constrain, constrained, context, conventional, cracked, creative, creed, culture, Defense, developmental, dialogue, dictated, discriminate, dMMR, DOR, economy, EHS, emerge, emergency, England, enrichment, enterprise, epidemic, equitably, ESMO, Estate, EUA, excellence, ExpirationIncluding, extracorporeal, fashion, febrile, firstMIND, FOP, freely, frontMIND, gender, geography, goal, graduate, Hall, harassment, home, HS, hybrid, IAI, Ib, ill, impede, inclusion, inclusive, infection, inMIND, Internet, invasive, job, Jopwell, Journal, Katherine, Labour, lenalidomide, lifeblood, lymph, marital, MCC, mDOR, median, membrane, mental, mentoring, microsatellite, military, mismatch, MONJUVI, Montreal, mortality, Motion, movement, myeloma, na, nausea, negligible, NIAID, Nimble, nonrefundable, North, numerical, orientation, outbreak, outset, outsourced, oxygen, oxygenation, pandemic, participatory, partnership, pathogenic, payroll, pemazyre, peptide, petitioner, philosophy, plamotamab, pneumonia, PoC, Pocket, post, prioritization, prioritize, proactive, prolonged, pronounced, proud, PRV, PTE, QD, quarantine, question, race, RAD, radio, RECIST, recurrent, reimposition, remdesivir, remote, remotely, reopened, reopening, repair, respiratory, resurgence, retaliation, retifanlimab, Revolutionizing, rituximab, Rodino, RUXCOVID, SCAC, sex, sexual, Shield, shutdown, slower, SMDP, SoC, Society, sought, SPC, standalone, stay, storm, strain, strong, suboptimal, suspected, sweat, sweeping, swollen, symposium, TABRECTA, television, Town, Treasury, trillion, TrOOP, Trump, tuition, uncollectible, underrepresented, underwritten, unpredictable, unusual, utmost, ventilation, veteran, virtual, voluntarily, vomiting, voucher, widespread, worth, Wuhan, XmAb

Removed: acceleration, actuarial, adjusted, affiliated, annum, assured, AtD, Bank, block, Brooke, concept, customary, deducting, deduction, derivative, discontinued, Extensionsand, flare, Israel, mature, minimum, moderate, Norway, partially, persuasive, PIM, placement, possession, proof, redeem, refund, refundable, released, rendered, RESET, Russia, satisfying, scaly, Securing, subside, tackle, transition, trustee, Turkey, Unionand, visit

From filing 10-K 2020 FY